secwatch.observer — SEC 8-K summary
======================================

Issuer:     LISATA THERAPEUTICS, INC. (LSTA)
CIK:        0000320017
Form:       8-K
Filed at:   2023-11-02T23:59:59+00:00
Accession:  0000320017-23-000062
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lisata Q3 net loss $5.3M; ASCEND ~95% enrolled, BOLSTER first patients treated
------------------------------------------------------------------------------

- Net loss of $5.3M in Q3 2023 (vs $37.4M prior year which included $30.4M merger costs); cash $54.4M.
- ASCEND study (~95% enrollment) received positive interim futility analysis; topline data from Cohort A expected as early as Q4 2024.
- First patients treated in BOLSTER basket trial for head and neck and cholangiocarcinoma cohorts.
- Orphan drug designations granted for LSTA1 in malignant glioma (U.S.) and pancreatic cancer (EU).
- Cash runway into early 2026; expected to fund all ongoing trials through data.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/320017/000032001723000062/0000320017-23-000062-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/320017/000032001723000062/clbs-20231102.htm
  HTML page:      https://secwatch.observer/filing/0000320017-23-000062

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer